Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telix PharmaceuticalsASX:TLX +7.65%57 Equity-to-Asset is 0.36 as of Dec. 2025, which is 5% below its 10-year median of 0.38. GuruFocus rates ASX:TLX with a GF Score™ of 57/100 and a GF Value™ of A$44.10 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Telix Pharmaceuticals ranks worse than 76.27% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Telix Pharmaceuticals Equity-to-Asset Related Terms
Telix Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TLX vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Telix Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (ASX:TLX) has a Equity-to-Asset of 0.36 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Telix Pharmaceuticals and its competitors. This is near median its historical median of 0.38. Over the past decade, Telix Pharmaceuticals' Equity-to-Asset has ranged from 0.02 to 0.99. According to the industry distribution chart, Telix Pharmaceuticals ranks #1080 out of 1416 companies in the Biotechnology industry, placing it in the top 76.3%.
Is Telix Pharmaceuticals' Equity-to-Asset too high?
Telix Pharmaceuticals' current Equity-to-Asset of 0.36 is near median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.99. The Biotechnology industry median Equity-to-Asset is 0.68. Telix Pharmaceuticals' value of 0.36 is 47.1% below this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #1080 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #1080 out of 1416 companies for Equity-to-Asset. This places Telix Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Telix Pharmaceuticals' value of 0.36 is 47.1% below this benchmark. Historically, Telix Pharmaceuticals' own Equity-to-Asset has ranged from 0.02 to 0.99 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 0.68, Telix Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current Equity-to-Asset of 0.36 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current Equity-to-Asset is 0.36, which is near median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (ASX:TLX) is currently considered Possible Value Trap. The stock's GF Value™ is A$44.10, compared to a current price of A$16.19 — trading 63.3% below its estimated fair value. The current Equity-to-Asset is 0.36, which is near median its 10-year median of 0.38 and 47.1% below the Biotechnology industry median of 0.68. Telix Pharmaceuticals' overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Telix Pharmaceuticals (ASX:TLX), the current Equity-to-Asset is 0.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (ASX:TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of A$16.19 is trading 63.3% below its estimated GF Value™ of A$44.10.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ASX:TLX:
Equity-to-Asset: 0.36 (near median its 10-year median of 0.38)
GF Value™: A$44.10 vs. price of A$16.19 (63.3% below fair value)
Industry Position: 47.1% below the Biotechnology median (#1080 of 1416)
No single metric tells the full story. See the ASX:TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
57GF Score
Get the complete analysis for ASX:TLX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TLX has been successfully added to your 
